Ohad Hammer

Bright Prospects for Micromet (Part 2)

You are absolutely right. Should have included that as an option, but I don't think that it's a preferred option for the company.

ohad

Immunogen and Seattle Genetics: Verging on an Inflection Point

Thanks,

Hopefully next week...

Immunogen and Seattle Genetics: Verging on an Inflection Point

Although IMGN and SGEN are not the only players in the ADC arena, they are the most focused and committed ones. Others such as WYE,IMMU and MEDX are active in the field but none chose to put the pedal to the metal like IMGN and SGEN did.

I don't know a lot about CMC-544's clinical development, as it seems that Wyeth is almost intentionally hiding it. Can you please post links for clinical data?
Ironically, SGEN's naked antibody seems to perform better than both AVE9633 and Mylotarg, so patients will have a drug that is both safe and efficacious. For more on that you can go to my previous SGEN article.

With respect to IMGN's technology, it seems to do the job in the case of T-DM1, which is more impressive than any ADC I am familiar with. Genentech is certainly sold on the technology but what do they know…